Xiangxue Pharmaceutical (300147) Fundamentals 2026 — Revenue Analysis | SniperIQ
Xiangxue Pharmaceutical (300147) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥4.3B, trading at ¥6.58 on the SHZ. This SniperIQ fundamentals page covers Xiangxue Pharmaceutical's valuation, profitability (net margin -93.1%), revenue (¥1.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xiangxue Pharmaceutical's market cap?
Xiangxue Pharmaceutical (300147) has a market capitalization of approximately ¥4.3B, trading at ¥6.58 on the SHZ. Market cap moves with the live share price.
How profitable is Xiangxue Pharmaceutical?
Xiangxue Pharmaceutical runs a net profit margin of -93.1%, a gross margin of 26.8%, and an operating margin of -50.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xiangxue Pharmaceutical generate?
Xiangxue Pharmaceutical reported revenue of ¥1.6B for fiscal year 2025, with net income of -¥1.4B and earnings per share (EPS) of -2.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Xiangxue Pharmaceutical pay a dividend?
Xiangxue Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Xiangxue Pharmaceutical financially healthy?
Xiangxue Pharmaceutical carries a debt-to-equity ratio of -3.05x and a current ratio of 0.24x, with a market beta of 0.50. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Xiangxue Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xiangxue Pharmaceutical (300147) the key facts are: market cap ¥4.3B, revenue ¥1.6B, 52-week range 5.9-12.79. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Xiangxue Pharmaceutical's full fundamentals live
Get Xiangxue Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.